Zimmer Biomet Holdings, Inc.
ZBH Healthcare Medical Devices
Zimmer Biomet Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $8.2 billion, up 7.20% from fiscal 2024. In the quarter to June 2026, revenue grew 4.80%, EPS grew 33.8%, free cash flow grew 13.1% and total debt fell 1.23%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years, revenue growth for five.
Follow ZBH
Zimmer Biomet Holdings, Inc. (ZBH) Shares outstanding
Zimmer Biomet Holdings, Inc.'s shares outstanding at the end of fiscal 2025 was $198.7M, unchanged from fiscal 2024. At the end of the quarter to 30 June 2026 it was $192.8M. Over the past ten years it has ranged from $189.8M (fiscal 2015) to $210.4M (fiscal 2021); the current reading is higher than 18% of that period. Zimmer Biomet Holdings, Inc. ranks 18th of 147 Medical Devices companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $198.7M | (2.55%) |
| FY2024 | $203.9M | (2.77%) |
| FY2023 | $209.7M | (0.29%) |
| FY2022 | $210.3M | (0.05%) |
| FY2021 | $210.4M | 1.64% |
| FY2020 | $207.0M | 0.15% |
| FY2019 | $206.7M | 1.57% |
| FY2018 | $203.5M | (0.10%) |
| FY2017 | $203.7M | 0.64% |
| FY2016 | $202.4M | 6.64% |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Jun 2026 | $192.8M | (1.53%) |
| Mar 2026 | $195.8M | (1.46%) |
| Dec 2025 | $198.7M | (0.05%) |
| Sep 2025 | $198.8M | 0.25% |
| 42 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| PHG Koninklijke Philips N.V. compare | $968.6M |
| GEHC GE HealthCare Technologies Inc. compare | $454.0M |
| SNN Smith & Nephew SNATS, Inc. compare | $449.4M |
| DXCM DexCom, Inc. compare | $390.1M |
| ZBH Zimmer Biomet Holdings, Inc. | $192.8M |
| GMED Globus Medical, Inc. compare | $137.4M |
| STE STERIS plc compare | $97.9M |
| PEN Penumbra, Inc. compare | $39.6M |
| BIO.B Bio-Rad Laboratories, Inc. compare | $26.8M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on ZBH
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement